sinc
ancient
time
natur
product
serv
major
sourc
drug
fifti
percent
today
pharmaceut
drug
deriv
natur
origin
interest
natur
product
sourc
new
drug
grow
due
mani
factor
discuss
n
articl
virus
resist
therapi
prophylaxi
longer
form
life
current
drug
avail
cure
viral
diseas
includ
acyclovir
model
natur
product
parent
order
combat
virus
devast
effect
n
human
anim
insect
crop
plant
fungi
bacteria
mani
research
effort
devot
discoveri
new
antivir
natur
product
recen
analysi
number
sourc
antivir
agent
report
mainli
annual
report
medicin
chemistri
fro
indic
seven
often
syntheti
c
agent
approv
fda
model
natur
product
parent
estim
approxim
speci
higher
plant
systemat
investig
presenc
bioactiv
compound
potenti
marin
environ
bare
tap
aim
review
provid
overview
central
role
natura
l
product
n
discov
develop
f
ne
w
antivir
drug
display
structur
plant
marin
microbi
origin
show
promis
vitro
antivir
activ
sinc
ancient
time
natur
product
serv
major
sourc
e
drug
abou
fift
percen
f
today
pharmaceutica
l
drug
ar
e
deriv
natura
l
origi
n
th
e
growin
g
inter
n
natura
l
product
sourc
f
ne
w
drug
ca
n
b
e
attribut
man
factor
includin
g
urgen
therapeut
need
th
e
wid
e
rang
e
f
bot
h
chemica
l
structur
biolog
activiti
f
natura
l
secondar
metabolit
th
e
adequac
f
bioactiv
natura
l
product
biochemica
l
molecula
r
probe
th
e
develop
f
recen
techniqu
accuratel
detect
isolat
e
structurallycharacter
th
e
bioactiv
e
natura
l
product
advanc
n
solv
th
e
deman
fo
r
suppl
f
compl
x
natura
l
product
histor
th
e
majorit
f
th
e
natura
l
productbas
drug
includin
g
cyclosporin
paclitaxel
camptothecin
deriv
first
discov
traditiona
l
cellbas
vitro
assay
befor
e
thei
r
rea
l
molecula
r
biolog
target
identifi
cellular
biolog
respons
natur
product
like
associ
wit
h
inher
properti
secondari
metabolit
defens
produc
organ
infecti
vira
l
diseas
remai
n
worldwid
e
problem
virus
hav
e
resist
therapi
prophylaxi
longer
form
f
lif
e
due
natur
total
depend
cell
infect
fo
r
multipl
surviv
peculiar
characterist
render
developmen
f
effectiv
e
antivira
l
chemotherapeuti
c
agent
ver
difficult
current
drug
avail
cure
viral
diseas
includin
g
acyclovi
r
know
n
antiherpeti
c
dru
g
whic
h
model
n
natura
l
produc
parent
n
ord
r
comba
virus
whic
h
devastatin
g
effect
n
human
anim
insect
cro
p
plant
fung
bacteria
mani
research
effort
hav
e
devot
discoveri
new
antivir
natur
product
although
search
natur
occurrin
g
product
whic
h
ca
n
interf
e
wit
h
vira
l
infect
bega
n
wit
h
th
e
success
isol
antibiot
microorgan
intens
synthet
antivir
agent
mainli
du
e
tendenc
f
virologist
wh
adop
ration
desig
n
f
antivira
l
agent
rath
r
tha
n
towar
empirici
especial
wit
h
th
e
progr
n
knowledg
f
vira
l
replicatio
n
moreov
ther
e
ar
e
som
e
problem
aris
screen
crude
extract
well
purificatio
n
identificatio
n
f
antivira
l
compon
fro
the
e
crud
e
extract
problem
becam
less
intens
recent
advanc
differen
chromatograph
spectroscopi
c
technolog
man
natura
l
synthet
compound
wer
e
foun
sho
w
vitro
antivira
l
activit
bu
much
le
effect
whe
n
test
vivo
thi
could
attribut
difficulti
n
dru
g
transportatio
n
th
e
cell
f
th
e
infect
tissu
e
especi
f
the
e
tissu
becom
e
inflamm
du
e
infect
man
antivir
activ
e
compound
ar
e
toxi
c
fo
r
therapeuti
c
applic
howev
natura
l
product
remai
n
th
e
be
resourc
e
fo
r
chemical
divers
ne
w
lea
entiti
tha
coul
serv
e
fo
r
futur
e
developmen
potent
safe
antivir
agent
recent
analysi
number
sourc
antivira
l
agent
report
mainl
n
th
e
annua
l
report
f
medicina
l
chemistri
fro
indic
tha
seve
n
ou
oft
n
syntheti
c
agent
approv
b
fd
betwe
n
ar
e
model
n
natura
l
product
paren
the
e
drug
famciclovi
r
ganciclovi
r
sorivudin
zidovudin
e
didanosin
e
zalcitabin
e
stavudin
aim
review
provid
overview
central
role
natur
product
discoveri
develop
new
antivir
drug
origin
latin
mean
viru
poison
venom
slime
word
viru
also
use
figur
n
sens
virulen
bitter
feel
stench
offens
odor
late
term
viru
bestow
newli
discov
class
pathogen
smaller
bacteria
studi
loui
pasteur
other
era
late
viru
defin
poison
infecti
disea
e
especi
foun
n
th
e
secretio
n
r
tissu
f
n
individua
l
r
anima
l
suffer
fro
infecti
diseas
earli
decad
twentieth
centuri
virus
identifi
infecti
agent
filterabl
e
invisibl
e
n
ligh
microscop
e
whic
h
superficial
distinguish
familiar
microorgan
today
virus
defin
noncellular
infecti
agent
vari
size
morpholog
complex
host
rang
affect
thei
r
host
howev
share
three
main
characterist
common
viru
consist
genom
either
rna
r
dn
cor
e
geneti
c
materi
whic
h
surround
b
protect
protei
n
shell
frequentl
thi
shel
l
enclos
insid
e
n
envelop
capsid
contain
protein
lipid
b
viru
replic
multipli
onl
aft
r
genet
materia
l
enter
host
cell
virus
absolut
dependen
n
host
cell
energyyieldin
g
proteinsynthes
machineri
henc
e
ar
e
parasit
th
e
genet
level
c
viru
multipl
cycl
includ
separ
genom
protect
shell
initi
step
viru
outsid
host
cell
consid
aliv
chromosom
interv
success
mitosi
individu
cell
divid
three
period
e
gl
perio
preced
dna
replic
averag
durat
hour
e
period
dna
replic
averag
durat
hour
e
period
n
cell
prepar
th
e
next
mitosi
averag
durat
hour
rna
protei
n
ar
e
synthes
whil
e
mitosi
proce
ie
th
e
metapha
e
whic
h
betwe
n
g
l
period
bu
ar
e
otherwis
synthes
throughou
th
e
multiplicatio
n
cycl
e
nongrow
cell
usual
arrest
n
gl
period
rest
stat
e
refer
go
norma
l
grovh
condit
cell
f
grow
cultur
multipli
unsynchron
manner
henc
cell
stage
cycl
present
age
cell
start
abou
passag
slow
growth
rate
amount
time
spend
go
eac
h
mitosi
gradual
increas
chromosom
complemen
chang
fro
normal
diploi
aneuploid
pattern
supernumerar
chromosom
final
fragment
th
e
cel
l
die
malignan
tissu
giv
e
ri
e
aneuploid
cel
l
line
tha
hav
e
infinit
e
lif
e
span
ar
e
know
n
continu
cell
line
main
featur
normal
anim
cell
compartment
dna
f
anim
cel
l
restrict
nucleu
cell
cycl
stage
except
durin
g
metapha
e
whe
n
nucleu
exist
synthesi
f
rn
occur
n
nucleu
mo
f
remain
messeng
r
rn
transf
r
rn
migrat
e
th
e
cytoplasm
ribosoma
l
rn
synthes
n
th
e
nucleolu
th
e
tw
ribosoma
l
subunit
ar
e
partl
assembl
nucleolu
nucleu
migrat
cytoplasm
protein
synthesi
proce
n
th
e
cytoplasm
th
e
mitochondria
whic
h
locat
onl
n
th
e
cytoplasm
contain
dna
rna
proteinsynthes
system
virus
replic
differ
way
case
viral
dna
rna
copi
repeatedli
viral
protein
synthes
insid
suitabl
host
cell
man
ne
w
vira
l
particl
ar
e
assembl
general
virus
replic
follow
stage
whic
h
ar
e
incorpor
int
th
e
host
plasm
membran
e
viral
nucleic
acid
enzym
capsid
protein
assembl
ne
w
vira
l
particl
genom
togeth
r
wit
h
thei
r
associ
rna
dna
polymeras
e
newli
form
viral
particl
releas
infect
cell
virus
usual
replicat
e
lytic
temper
pathway
lytic
pathway
stage
proce
quickli
viru
releas
host
cell
undergo
lysi
ruptur
die
lo
content
temperat
e
pathway
th
e
viru
doe
kil
l
th
e
ho
cel
l
bu
th
e
infect
enter
period
latenc
viral
gene
remain
inact
insid
th
e
ho
cell
n
som
e
case
f
latenc
th
e
vira
l
gene
becom
e
integr
host
dna
replic
along
pass
along
daughter
cell
time
damag
dna
event
may
activ
transcript
viral
gene
therefor
new
viral
particl
produc
infect
cell
destroy
propos
target
specif
antivira
l
chemotherap
ar
e
illustr
n
figur
e
ca
n
b
e
summar
adsorpt
viral
particl
host
cell
n
host
cell
infecti
viral
particl
uncoat
releas
transport
f
viral
nucleic
acid
core
protein
c
acid
polymeras
releas
andor
activ
n
mrna
polypeptid
earli
protein
n
mrna
n
nucleic
acid
n
synthesi
late
protein
l
polypeptid
cleavag
use
polypeptid
matur
assemblag
viral
capsid
precursor
n
nucleic
acid
protein
represen
th
e
mai
n
vira
l
compon
protein
ar
e
th
e
sol
e
constitu
f
capsid
major
componen
envelop
also
associ
nucleic
acid
mani
virus
core
protein
viral
protein
wide
rang
molecular
weight
rang
dalton
viral
protein
also
vari
number
virus
poss
three
speci
other
contain
protein
speci
member
f
th
e
sam
e
viru
famil
displa
almo
th
e
sam
e
highl
characterist
electrophoret
protein
pattern
glycoprotein
vira
l
envelop
usual
contai
n
glycopotein
n
th
e
form
f
oligomer
spike
project
th
e
carbohydr
moieti
glycoprotein
form
f
oligosaccharid
monosaccharid
unit
link
polypeptid
backbon
nand
oglycosidi
c
bond
involvin
g
asparagin
e
serin
e
r
threonin
respect
thei
r
main
compon
galacto
e
galactosamin
gluco
e
glucoseamin
fucos
manno
e
siali
c
aci
whic
h
alway
occupi
termin
posit
exampl
viral
protein
special
function
hemagglutinin
man
anima
l
virus
eg
ortho
paramyxovirus
agglutin
red
blood
cell
certain
anim
speci
mean
tha
the
e
cell
contai
n
receptor
fo
r
certai
n
surfac
e
compon
viral
particl
act
cell
attach
protein
glycoprotein
known
hemagglutinin
viral
hemagglutinin
could
use
quantit
measur
enzym
anima
l
vira
l
particl
oft
n
contai
n
enzym
tabl
e
enzym
virusspecif
n
addit
enzym
summar
tabl
e
virus
oft
n
contai
n
oth
r
enzym
amon
g
ar
e
th
e
enzym
tha
modif
bot
h
end
f
mrn
molecul
synthes
b
cappin
g
enzym
poli
polymeras
protei
n
kinas
deoxyribonucleas
dnadependen
phosphohydrolas
topoisomeras
also
often
present
virus
homeostasi
cell
number
multicellular
organ
maintain
balanc
betwe
n
cel
l
proliferatio
n
physiolog
c
program
cel
l
death
apoptosi
process
cell
undergo
physiolog
death
respons
stimulu
predictabl
e
seri
f
morphological
defin
event
divid
int
two
stage
name
breakdown
nucleu
alteratio
n
f
th
e
cel
l
shap
e
th
e
plasm
membran
e
permeabl
th
e
consequ
f
apoptosi
ar
e
th
e
fragmentatio
n
f
nuclear
dna
zeiosi
boil
f
cytopla
associ
wit
h
th
e
bleb
increas
granular
plasma
membran
fracturin
g
cel
l
int
subcellula
r
dnacontainin
g
apoptoti
c
bodi
apoptosi
process
differ
fro
necroti
c
cell
death
involv
f
lysosoma
l
enzym
leakag
cytoplasm
swell
cell
actual
ruptur
plasma
membran
necrosi
often
induc
agent
affect
membran
e
integr
gener
protei
n
synthesi
r
energ
metabol
apoptosi
ca
n
b
e
induc
b
variet
f
stimuli
eg
steroid
cytokin
dnadamag
agent
growth
factor
withdrawa
l
case
f
b
cell
antigenreceptor
engag
apoptosi
also
mechan
b
whic
h
cytotoxi
c
lymphocyt
kil
l
thei
r
target
man
virus
ca
n
induc
e
apoptosi
n
infect
cell
whil
e
man
oth
r
virus
especi
transformin
g
virus
ca
n
inhibi
apoptosi
allo
w
fo
r
cel
l
transform
th
e
nuclea
r
chang
durin
g
apoptosi
induc
e
chromati
n
virus
cau
e
severa
l
hundr
infecti
diseas
man
plant
aft
r
success
penetratin
g
cell
wall
reduc
yield
varieti
f
crop
includin
g
tobacco
potato
tomato
wel
l
man
oth
r
veget
inducin
g
seriou
economi
c
damag
som
e
insect
tha
fee
plant
assi
n
vira
l
infect
vira
l
particl
b
e
clingin
g
the
e
insect
pierc
suck
devic
devic
penetr
plant
cell
infectio
n
occur
mani
anima
l
virus
infec
human
anim
causin
g
severa
l
seriou
diseas
tabl
e
present
summar
f
som
e
anima
l
virus
th
e
diseas
induc
viroid
ar
e
plant
pathogen
whic
h
consi
f
nake
strand
r
circl
f
rna
protein
coat
viroid
mere
snippet
gene
smaller
small
know
n
vira
l
dn
r
rn
molecul
e
ca
n
hav
e
damag
effect
n
citru
avocado
potato
oth
r
cro
p
plant
appar
enzym
alread
presen
n
ho
cel
l
synthesiz
e
viroi
rna
use
new
viroid
rna
templat
build
new
viroid
unidentifi
infecti
agent
caus
rare
fatal
diseas
nervou
system
includ
scrapi
sheep
kuru
crutzfeldtjaco
b
mad
cow
disea
e
n
human
probabl
the
e
diseas
ar
e
caus
b
infecti
protei
n
particl
tentativel
name
prion
prion
migh
b
e
synthes
accordin
g
informatio
n
n
mutat
gene
research
studi
scrapi
hav
e
isol
th
e
gen
e
codin
g
fo
r
alter
form
f
protein
infect
cell
virus
either
measur
infecti
unit
ie
term
abil
infect
multipl
produc
progeni
viral
particl
regardless
function
infecti
agent
titrat
mean
th
e
measuremen
f
amoun
f
viru
n
term
f
th
e
number
infecti
unit
per
unit
volum
plaqu
format
monolay
suscept
cell
inocul
small
aliquot
serial
dilut
f
th
e
viru
suspensio
n
titrat
whenev
r
vira
l
particl
infect
cell
progeni
viru
particl
produc
releas
immedi
infect
adjoinin
g
cell
process
repeat
incubatio
n
day
r
area
f
infect
cell
develo
p
plaqu
tha
ca
n
b
e
see
n
nake
eye
agar
frequent
incorpor
n
medium
ensur
th
e
liber
progen
viru
particl
n
th
e
mediu
diffu
e
away
initiat
e
separat
e
r
secondar
plaqu
infect
cell
mu
differ
n
recogniz
manner
non
infect
one
ie
must
complet
destroy
becom
detach
surfac
n
grow
r
possess
stainin
g
properti
differen
fro
tho
e
f
normal
cell
mo
commo
n
metho
visual
plaqu
appli
neutra
l
r
crystal
violet
infect
cel
l
monolay
count
number
n
stain
area
titer
ar
e
express
n
term
f
numb
r
f
plaqueform
unit
pfu
pe
r
millilit
ther
e
linea
r
relationshi
p
linear
doserespons
curv
amount
viru
numb
r
plaqu
produc
whic
h
indic
tha
eac
h
plaqu
e
produc
b
singl
vira
l
particl
th
e
viru
progeni
n
eac
h
plaqu
e
ar
e
clone
viru
stock
deriv
fro
singl
e
plaqu
name
plaqu
e
purifi
whic
h
import
n
isolatin
g
pur
e
viru
strain
plaqu
e
formatio
n
th
e
mo
desir
metho
f
viral
titrat
becau
e
econom
technical
simpl
howev
virus
measur
thi
way
due
lack
host
cell
develop
desir
cytopath
effect
cpe
mani
anima
l
virus
ge
adsorb
b
red
bloo
cell
rbc
f
variou
anim
speci
viral
particl
multival
ie
adsorb
e
cel
l
time
n
practic
th
e
maximu
numb
r
f
cell
wit
h
particular
viru
combin
two
sinc
rbc
bigger
viral
particl
viruscel
mixtur
number
cell
exce
number
viral
particl
small
number
f
cell
dimer
may
b
e
form
gener
undetect
number
f
viral
particl
exceed
number
cell
lattic
agglutin
cell
form
tha
settl
characterist
readili
distinguish
manner
th
e
settl
pattern
exhibit
b
unagglutin
cell
hemagglutinatio
n
assa
th
e
determin
f
viru
exactli
agglutin
standard
numb
r
rbc
number
viral
particl
requir
fo
r
readili
calcul
slightli
higher
number
cell
hemagglutin
highli
accur
rapid
assay
vitro
antivir
screen
assay
vira
l
infectivit
n
cultur
cell
determin
durin
g
viru
multipl
n
presenc
e
f
singl
e
test
compoun
r
extrac
r
extracellular
incub
current
antivir
chemotherapi
research
n
antivir
chemotherapi
start
around
earli
search
fo
r
antic
r
drug
reveal
severa
l
new
compound
tha
inhibi
viral
dn
synthesi
eg
th
e
pyrimidin
analo
g
idoxuridin
e
whic
h
wa
later
approv
topica
l
treatmen
fo
r
herp
kerat
sinc
e
research
effort
wer
e
focus
n
purin
pyrimidin
nucleosid
e
analog
emerg
aid
epidem
research
antivir
gener
specifical
antihi
v
becam
e
high
prioriti
man
f
retroviru
protein
purifi
character
sake
design
drug
would
select
inhibit
critic
enzym
hiv
revers
transcriptas
proteas
requir
final
packag
viru
particl
e
previousl
azidothymidin
azt
deoxythymidin
analo
g
tha
al
requir
anaboli
c
phosphorylatio
n
activ
competitivel
inhibit
deoxythymidin
e
triphosph
fo
r
th
e
rt
al
act
chai
n
terminato
r
n
th
e
synthesi
pro
viral
dna
activ
human
cell
lymphotropi
c
virus
resist
occur
due
mutat
rt
gene
didanosin
syntheti
c
analo
g
f
deoxyadenosin
anabol
activ
inhibit
viral
replic
resist
typic
associ
mutat
codon
zalcitabin
pyrimidin
nucleosid
inhibit
replic
similar
mechan
mutat
codon
induc
resist
associ
decreas
suscept
e
thymidin
analog
also
requir
metabol
activ
activ
e
nucleosid
analog
vitro
inhibit
hbv
inhibit
hivrt
show
synergist
effec
wit
h
requir
metabol
phosphoryl
high
level
resist
develop
mutat
codon
r
specif
inhibitor
proteas
essenti
th
e
product
f
matur
infecti
virion
current
clinic
approv
treatment
infect
r
inhibitor
hiv
proteas
high
bioavail
metabol
hepat
cytochrom
oxidas
system
henc
suffer
sever
drug
interact
r
synthet
peptidelik
analog
inhibit
activ
proteas
prevent
cleavag
viral
polyprotein
n
guanosin
e
analo
g
tha
intracellularl
phosphoryl
b
host
cell
enzym
despit
mechan
yet
fulli
elucid
appar
interfer
synthesi
guanosin
e
triphosphat
e
inhibi
cappin
g
f
vira
l
mrn
viral
rnadepend
polymeras
triphosph
deriv
inhibit
replic
f
wide
rang
f
rna
dna
virus
includ
influenz
b
parainfluenza
respir
syncytia
l
viru
rsv
paramyxoviru
hcv
four
basi
c
approach
ar
e
conduct
fo
r
plan
selectio
n
fo
r
antivira
l
screen
assay
rando
collectio
n
f
plant
follow
b
ma
screen
approach
follow
exist
lead
approac
h
second
third
approach
ar
e
th
e
mo
favor
one
becau
e
f
thei
r
costeffectiv
e
applic
select
base
folklor
use
prove
five
time
higher
percentag
f
activ
lead
approach
random
approach
usual
afford
mor
e
novel
compound
antivir
activ
combin
ethnomed
phytochem
taxonom
approach
consid
best
compromis
differ
cel
l
culturebas
assay
ar
e
currentl
availabl
e
ca
n
b
e
success
appli
fo
r
plan
extract
pur
e
compound
antivira
l
agent
tha
interf
e
wit
h
e
r
mor
e
vira
l
biosyntheti
c
dynami
c
process
good
candid
clinic
use
drug
virucid
agent
extracellularl
inactivat
e
viru
infectivit
ar
e
rath
r
candid
antisept
th
e
ke
factor
tha
determin
e
th
e
selectio
n
f
th
e
assa
system
simplic
accuraci
reproduc
selectivit
specif
evaluatio
n
f
th
e
antivira
l
potenc
f
test
compound
along
cytotox
therapeut
index
given
viral
system
calcul
th
e
therapeut
ind
x
defin
ratio
f
maximum
drug
concentr
normal
cell
grovrth
inhibit
minimum
drug
concentr
sometim
viru
inhibit
rel
potenc
new
antivir
agent
compar
exist
approv
drug
vivo
test
new
vitro
activ
antivir
agen
consid
th
e
key
ste
p
befor
e
huma
n
clinica
l
trial
thi
mode
l
shoul
predic
anim
metabol
process
g
tha
compoun
wil
l
resist
adversel
affec
immun
system
two
usefu
l
anima
l
model
ar
e
usual
employ
heterologu
r
homologu
heterologu
system
diseas
induc
viru
n
anim
origi
n
n
experimenta
l
anima
l
tha
mimic
th
e
huma
n
diseas
sever
review
hav
e
bee
n
publish
dealin
g
wit
h
natura
l
productsderiv
antivira
l
compound
present
ar
e
tw
plantderiv
compound
clinic
develop
f
calanolid
coumari
n
isol
fro
th
e
malaysia
n
rainfor
tree
calophyllum
langigerum
b
th
e
us
nation
canc
r
institut
e
show
poten
hivr
inhibitor
activit
vitro
studi
f
demonstr
activit
again
includin
g
az
oth
r
nonnucleosid
r
inhibitorsresistan
strain
al
show
synergisti
c
anti
hiv
activ
n
combin
nucleosid
rt
inhibitor
overcom
e
th
e
difficult
f
suppl
f
tota
l
chemica
l
synthesi
accomplish
n
jun
e
clinica
l
developmen
f
wa
start
potenti
drug
treatment
aid
singl
center
h
us
pha
e
l
clinica
l
tria
l
f
wa
start
ass
safet
toler
mixtur
e
f
natura
l
oligomeri
c
proanthocyanidin
u
p
molecular
weigh
dalton
isol
th
e
late
x
f
latin
america
n
plan
croton
lechleri
show
potent
vitro
activ
hsv
varieti
dna
rna
virus
virend
whic
h
topic
formulatio
n
f
evalu
n
phase
ii
clinic
trial
treatment
genit
herp
combin
acyclovir
trial
later
suspend
prove
virend
addit
benefit
use
oral
acyclovir
alon
provir
oral
formul
f
sfsob
prove
safe
well
toler
phase
trial
ineffect
n
phase
ii
treatment
rsv
sinc
adequ
absorpt
patient
howev
provir
prove
effectiv
e
symptomati
c
treatmen
f
travel
diarrh
throug
h
restoratio
n
f
normal
bowel
function
prevent
recurr
alkaloid
heterogen
group
compound
link
common
possess
f
basi
c
natur
containin
g
e
r
mor
e
nitrog
n
atom
usual
combin
part
heterocycl
system
precursor
usual
amino
acid
exert
certain
biolog
activ
mani
alkaloid
also
foun
n
anim
human
coul
exer
profound
pharmacologica
l
activit
tabl
e
illustr
variou
alkaloid
activ
mani
anim
virus
lycorin
pretazettin
apqrph
oliverin
pgnzqphgnanthrid
chelidonin
schumannificin
flavqiioid
opium
morphin
codein
papaverin
phenantl
iroquinozolizidin
cryptopleurin
pipgrid
l
deoxymannojirimycin
ahomonojirimycin
protoberberin
berberin
columbamin
e
palmatin
pvrrolizidin
austra
l
ine
ouinolineisoquinolin
tabl
summar
antivir
activ
plant
nonplant
carbohydr
chromon
furanocoumarin
flavonoid
ar
e
common
constitu
n
mani
plan
famili
coumarin
ar
e
specif
abundan
n
famili
rutacea
umbellifera
e
yield
coul
sometim
reac
h
u
p
f
dr
plant
weight
tabl
e
illustr
variou
antivira
l
activiti
chromon
coumarin
flavonoid
lignan
ar
e
widesprea
secondar
metabolit
n
plant
kingdom
occur
mani
part
plant
especi
wood
resin
bark
tree
also
found
n
mani
root
leav
flower
fruit
seed
evid
lignan
play
major
rol
e
plantplant
plantinsect
plantfungu
interact
chemica
l
structur
f
e
r
l
g
n
n
h
n
n
l
g
n
n
anolignan
justicidin
lignan
ar
e
diver
e
compl
x
despit
e
ar
e
essential
dimer
f
phenylpropanoid
unit
link
central
carbon
sid
e
chain
present
six
lignan
subgroup
butan
deriv
lignanolicl
butanolid
monoepoxylignan
tetrahydrofura
n
deriv
bisepoxylignan
octan
deriv
cyclolignan
tetrahydronaphthalen
cyclolignan
base
n
naphthalen
phenol
benzoquinon
naphthoquinon
anthraquinon
phenylpropanoid
ar
e
abund
secondari
metabolit
plant
tabl
illustr
report
antivira
l
activiti
plan
secondari
metabolit
tannin
ar
e
phenoli
c
compound
tha
ar
e
abundan
n
plan
kingdom
basic
ther
e
ar
e
tw
type
f
tannin
hydrolysabl
e
typ
e
whic
h
usual
consist
simpl
phenol
acid
eg
gallic
acid
link
sugar
th
e
condens
typ
e
simila
r
flavonoid
th
e
know
n
medicin
tannincontainin
g
plan
lemo
n
bal
melissa
officinali
labiata
extens
studi
antivir
agent
leav
plant
contain
abou
dri
weight
f
tannin
ar
e
mainli
construct
caffei
c
acid
cream
contain
special
prepar
dri
extract
lemon
balm
leav
introduc
german
market
loca
l
therap
f
herp
infect
f
ski
n
effect
f
cream
n
th
e
topica
l
treatmen
statistical
significan
proven
b
clinic
studi
decis
indic
constitu
extract
plant
could
serv
use
lead
develop
antivir
drug
futur
terpenoid
also
abund
secondari
metabolit
condens
tannin
catgghinjg
aci
condens
n
n
n
p
v
e
n
n
n
cinnamtannin
galloy
l
catechi
n
epicatechin
procyanidin
b
plant
world
terpenoid
essenti
deriv
basic
isopren
unit
the
e
ar
e
classifi
monoterpen
cio
sesquiterpen
diterpen
triterpen
sterol
saponin
seve
n
hundr
polyacetylen
hav
e
bee
n
isol
fa
r
mainl
plant
belongin
g
th
e
famil
f
asteracea
umbellifera
e
campanulacea
polyacetylen
occu
r
princip
straight
chai
n
polyin
allen
phenyl
thiophenyl
thioether
spiroketalenoeth
r
deriv
quit
high
yield
thiophen
relat
sulfur
compound
usual
group
togeth
r
wit
h
th
e
polyacetylen
becau
e
f
thei
r
common
biosyntheti
c
pathway
plantder
lacton
butenolid
phospholipid
sho
w
antivira
l
activ
th
e
antivira
l
activ
f
thiophen
polyacetylen
lacton
butenolid
phospholipid
plant
origin
report
tabl
thiarubin
thiophenea
phenylheptatriyn
addit
protein
papii
pap
found
n
rel
smaller
amount
subsequ
rip
found
n
plant
exhibit
similar
antivir
activ
eg
tritin
fro
triticum
aestivum
seed
geloni
n
fro
gelonium
multiflorum
seed
momordin
fro
momordica
charantia
seed
sapori
n
fro
saponaria
officinali
seed
dianthin
fro
dianthu
caryophyllu
leaf
tricosanthi
n
trichosanth
kirilowii
bryodin
bryonia
dioica
bougainvillea
antivira
l
protei
n
ba
p
fro
bougainvillea
spectabili
roo
varieti
nicotiana
glutinosa
produc
protein
call
avf
afford
som
e
protectio
n
again
tm
v
b
restrictin
g
lesion
n
n
analog
mann
r
interferon
av
f
glycoprotei
n
whic
h
termin
phosphoryl
wit
h
dalton
molecula
r
weight
th
e
mechan
action
avf
yet
establish
meliacin
n
antivira
l
glycopeptid
e
f
molecula
r
weigh
dalton
isol
th
e
leav
melia
azedarach
meliacea
aprotinin
anoth
r
plantder
antivira
l
polypeptid
e
whic
h
specif
inhibi
myxovirus
especial
influenz
aportinin
e
known
proteas
inhibitor
act
interferin
g
wit
h
essentia
l
step
cleavag
precursor
hao
subunit
polypeptid
henc
prevent
viral
infect
mani
plantder
di
tripeptid
wer
e
prove
activ
again
hsv
measl
viru
mv
the
e
peptid
consi
mainl
f
carbobenzoxi
deriv
f
phenylalanin
e
cationi
c
peptid
ar
e
use
natur
antibiot
produc
n
respons
infect
n
virtual
mo
organ
includin
g
plant
insect
cationi
c
peptid
protein
ar
e
w
proceedin
g
throug
h
clinica
l
trial
topica
l
antibiot
antiendotoxin
sever
thousan
plan
extract
hav
e
bee
n
show
n
poss
vitro
antivir
activit
wit
h
littl
e
overla
p
n
speci
betwe
n
studi
n
mo
case
th
e
assa
method
ar
e
design
detec
virucid
prophylacti
c
activ
defin
e
extract
tha
interf
e
wit
h
vira
l
replicatio
n
n
cultur
cell
aqueou
organi
c
extract
general
bee
n
prove
equal
fruitfu
l
henc
feasibl
asser
e
metho
extractio
n
prefer
furth
r
characterizatio
n
f
th
e
activ
e
constitu
activ
extract
reveal
use
compound
mani
f
activ
e
extract
tur
n
ou
b
e
identica
l
r
relat
th
e
previous
describ
structur
class
yet
also
may
possibl
som
e
nove
l
phytochem
tabl
e
summar
som
e
f
th
e
mo
activ
extract
literatur
marin
e
speci
comprisin
g
approximatel
e
hal
f
f
tota
l
globa
l
biodivers
fo
r
whic
h
estim
rang
e
betwe
n
x
speci
f
prokaryot
eukaryot
organ
marin
macrofauna
repres
broader
rang
e
taxonom
diversit
found
n
terrestri
evironmen
typic
eukaryot
possess
gene
global
marin
macrofauna
ar
e
sourc
x
x
primari
product
associ
extensiv
e
rang
e
f
secondar
metabolit
present
fe
w
thousan
nove
l
compound
fro
marin
e
origi
n
hav
e
bee
n
identifi
the
e
compound
reveal
uniqu
chemic
pharmacolog
term
howev
onl
fe
w
promis
therapeuti
c
lead
mani
marinederiv
peptid
alkaloid
protein
nucleosid
acontain
compound
show
n
activ
again
severa
l
vira
l
speci
tabl
illustr
activ
antivir
activ
variou
marinederiv
terpenoid
steroid
carotenoid
summar
tabl
halogen
cyclohexadienon
sggqviitgrpgng
avarol
tabl
contd
polysaccharid
green
marin
alga
ulva
lactuca
inhibit
reproduct
mani
human
avian
influenza
virus
acid
hydrolysi
thi
polysaccharid
e
reveal
th
e
presenc
e
f
arabinos
xylos
rhamnos
galactos
manno
e
gluco
e
n
rati
f
respect
along
unidentifi
suga
r
treatment
f
laminari
n
isol
fro
th
e
marin
e
alg
laminaria
cichorioid
b
e
fro
marin
e
invertebr
transform
n
int
highl
efficien
preparatio
n
again
tobacco
mosai
c
viru
name
antivi
r
polysaccharid
compos
f
mannos
galactos
glucos
uron
acid
sulfat
group
wtwt
obtain
marin
microalga
cochlodinium
polykrikoid
sho
w
potent
inhibitor
activiti
influenz
virus
typ
e
b
respiratori
syncytia
l
virus
typ
e
b
parainfluenza
virus
typ
e
cytotoxicit
r
inhibitio
n
th
e
blood
coagul
observ
ligml
unusua
l
sulfat
manno
e
homopolysaccharid
isol
fro
th
e
pacif
tunicat
e
didemnum
moll
show
vitro
antihi
v
activ
th
e
nmr
dat
polysaccharid
reveal
consist
f
sequenc
f
manno
e
unit
join
throug
h
p
glycosidi
c
linkag
natur
sulfat
mucopolysaccharid
e
extract
fro
marin
plan
dinoflagellata
n
artificia
l
sulfat
polysaccharid
e
prepar
fro
marin
pseudomona
display
antivira
l
activ
again
zidovudineresistan
influenza
virus
b
respiratori
syncytia
l
viru
measl
viru
without
displayin
g
cytotoxicit
r
inhibit
f
blood
coagulatio
n
f
host
cell
tabl
illustr
report
antivir
activ
common
marin
e
secondari
metabolit
polyacetylen
quinonespyron
macrolid
prostaglandin
human
dream
find
n
antivir
antibiot
microbi
origin
select
affect
viral
host
cell
similar
manner
th
e
regula
r
antibiot
ha
becom
e
realiti
howev
severa
l
microbialderiv
metabolit
sho
w
promisin
g
activ
th
e
us
e
f
microb
modif
syntheti
c
compound
r
accompli
h
specifi
c
desir
reactio
n
commo
n
n
pharmaceutica
l
industri
adenin
e
arabinosid
ara
approv
clinic
investig
also
produc
b
streptomyc
p
exampl
f
secondar
metabolit
fro
microbia
l
origi
n
tha
sho
w
antivira
l
activiti
ar
e
present
rifamycin
ar
e
microbialderiv
macrolid
isol
n
actinomycet
streptomyc
mediterranei
obtain
soil
pine
forest
southern
franc
rifamycin
b
lea
toxic
additio
n
f
diethylbarbituri
c
aci
th
e
fermentatio
n
medium
result
n
th
e
productio
n
f
rifampici
n
th
e
semisyntheti
c
derivativ
e
f
rifamycin
rifamycin
sho
w
vitro
vivo
antipoxyvirus
eg
vv
activ
activ
appar
du
e
inhibit
earli
step
viral
morphogenesi
affect
th
e
assembl
f
immatur
e
vira
l
particl
inhibitor
activ
rifamycin
n
retrovirus
also
report
mani
natur
semisyntheti
c
rifamycin
inhibi
th
e
virio
n
rnadependen
dn
polymeras
rt
rifamycin
b
wa
report
activ
e
again
murin
sarcom
viru
msv
du
e
rt
focu
formatio
n
cel
l
transform
inhibitor
activ
rifamycin
antibiot
also
inhibit
rt
rauuscher
leukemia
viru
prevent
leukomogen
activ
streptovaricin
b
tolypomycin
geldanamycin
ar
e
exampl
ansamycin
whic
h
ar
e
chemical
relat
rifamycin
th
e
streptovaricin
tolypomycin
resembl
e
rifamycin
n
rtinhibitor
activ
streptovaricin
b
inhibit
replic
f
poxvirus
inhibit
earl
stage
f
mrn
synthesi
inhibitio
n
f
focu
format
msv
streptovaricin
also
report
gliotoxin
fungal
metabolit
isol
aspergillu
terreu
foun
hav
e
antibacteri
antitumo
r
antifunga
l
effect
gliotoxin
acet
inhibit
cpe
polioviru
monkey
kidney
cell
cultur
due
earli
stag
e
inhibit
f
rna
viral
replic
gliotoxin
also
inhibit
influenza
virusinduc
rna
polymeras
arantonin
relat
compound
isol
arachniotu
aureu
dixidi
aspergillu
terreu
show
rt
inhibitori
activ
activ
attribut
epidithiapiperazinedion
moieti
case
sporidesmin
distamycin
n
oligopeptid
isol
fro
streptomyc
distallicu
inhibit
transcript
replic
dna
virus
along
relat
semisynthet
analog
exampl
dna
virus
inhibit
group
vaccinia
viru
distamycin
also
show
inhibitori
activ
rt
retrovirus
daunomycin
doxorubicin
anthracyclin
glycosid
isol
streptomyc
peucetiu
compound
use
cancer
chemotherapi
du
e
abil
bind
dna
compound
inhibit
rt
product
murin
leukemia
viru
actinomycin
peptid
antibiot
produc
streptomyc
parvulu
interact
cellular
dna
inhibit
replic
mammalian
virus
tha
depen
n
cellula
r
function
eg
rabi
viru
mithramycin
relat
compoun
tha
inhibit
influenz
pseudorabi
virus
probabl
du
e
inhibitio
n
f
ho
cel
l
rn
polymeras
ii
cordyceptin
ferment
produc
f
th
e
fung
aspergillu
nidulan
cordycep
militari
cordyceptin
inhibit
synthesi
mrna
henc
replic
f
rna
dna
virus
toyocamycin
anoth
r
adenosin
e
derivativ
e
produc
b
streptomyc
toyocaensi
compoun
selectivel
inhibit
th
e
ribosom
rn
synthesi
n
fibroblast
th
e
synthesi
f
adenovirusspecif
mrn
also
inhibit
sinefungin
n
adenin
e
deriv
isol
fro
streptomyc
griseolu
effectivel
inhibit
v
v
mrn
jmethyltransferas
henc
inhibit
methyl
mrn
bilay
structur
filipin
show
activ
again
vsv
less
degre
influenza
rauscher
leukemia
virion
amphotericin
b
anoth
relat
antifung
antibiot
methyl
ester
activ
vv
sv
vsv
less
cytotox
improv
water
solubl
aphidicolin
tetracycli
c
diterpenoid
produc
b
th
e
fungu
cephalosporium
aphilicola
abil
inhibit
vv
herpet
kerat
rabbit
mechan
compound
yet
establish
cytochalasin
b
metabolit
f
mol
helminthosporium
dermatoideum
inhibit
hexos
transport
n
cell
henc
use
fo
r
th
e
stud
f
virusspecifi
c
glycoprotei
n
synthesi
show
potent
inhibitor
activit
again
apparentl
du
e
th
e
inhibit
viral
glycosyl
cytochalasin
close
relat
compound
tha
show
activit
again
adenoviru
bu
enhanc
th
e
infect
polioviru
parainfluenza
phenol
acid
isol
penicillium
sp
show
inhibitori
activ
vv
semliki
forest
influenza
virus
coxsackieviru
effect
probabl
due
cytotox
addit
antivira
l
microbialderiv
metabolit
summar
n
tabl
n
urgen
nee
identif
nove
l
activ
e
chemotyp
lea
fo
r
effect
antivira
l
chemotherapi
recen
year
hav
e
witness
grea
advanc
area
enorm
natur
product
antivir
agent
start
b
e
express
n
th
e
f
antivira
l
chemotherapi
thi
repres
b
fda
approva
l
fo
r
clinica
l
investigatio
n
f
two
plantderiv
compound
addit
one
compound
marin
origin
one
microbialderiv
compound
ou
f
te
n
syntheti
c
approv
drug
seve
n
wer
e
model
n
natur
produc
pare
n
developmen
f
recen
techniqu
derepl
accuratel
detect
isol
structural
defin
e
autom
assa
th
e
bioactiv
e
natura
l
product
result
lead
antivir
agent
estim
onl
f
th
e
approximatel
speci
f
high
r
plant
bee
n
systematical
investig
fo
r
th
e
presenc
e
f
bioactiv
e
compound
potenti
marin
environ
bare
bee
n
tap
consequ
natura
l
product
represen
potentia
l
antivira
l
lead
resourc
imagin
discover
